# ActX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actx

- Industry: Healthcare IT
- Headquarters: Seattle, US
- Website: www.actx.com
- Total disclosed funding: $1.9M
- Latest round: Seed (Jan 9, 2014)
- Investors on record: 1

## About

ActX is a healthcare technology company specializing in personalized medical care by integrating genetic information into clinical practices to enhance patient treatment decisions.Founded in 2012 in Seattle, US, ActX provides a platform that enables healthcare providers to incorporate genetic data into patient care. The company raised USD 1.90 mn in Seed funding led by Alliance of Angels in January 2014, which is also the only funding deal recorded. Andres Pradilla, the founder, has a background in developing healthcare solutions.ActX specializes in personalized medical care through the integration of genetic information into healthcare practices. Their core offering involves a genetic information platform that provides healthcare providers with actionable insights derived from a patient's genetic data, enhancing clinical decision-making by identifying potential health risks and tailoring medical treatments to individual patients. ActX primarily targets healthcare providers in the United States, including hospitals and physician groups, to facilitate more effective and personalized patient care.ActX generates revenue through partnerships with healthcare institutions and direct transactions with medical providers. Their business model includes subscription-based services that allow clients to access their genetic data platform for interpreting genetic test results, promoting better patient outcomes. The revenue structure typically involves annual contracts that provide training, support, and updates, ensuring that healthcare providers can effectively integrate genetic information into their practices.ActX plans to utilize the recent USD 1.90 mn funding raised in January 2014 to enhance its genetic information platform and introduce new features aimed at improving clinical utility. The company is exploring opportunities to expand its services into additional markets, specifically targeting growth in Europe and Asia by 2025. This initiative will focus on adapting their platform to meet the regulatory and clinical needs of these regions.

## Funding rounds

- Seed, Jan 9, 2014, $1.9M — Alliance of Angels

## Investors

- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Seed